LivaNova PLC is selling its surgical heart valve business to Swiss private equity firm Gyrus Capital for €60m ($73m), the companies announced on 3 December.
LivaNova’s heart valve business includes the Perceval sutureless aortic valve, along with the Solo Smart aortic pericardial tissue valve with...






